ProMetic Life Sciences Inc., a biopharmaceutical company, has announced new and positive data on two of the company's orally active anti-fibrotic drug candidates.
In a standard animal model used to mimic the long term detrimental effects of diabetes on the kidney and the liver, ProMetic's once a day oral treatment with PBI-4050 demonstrated a significant reduction in kidney hyperfiltration, proteinuria and hepatic steatosis.
These results suggest that PBI-4050 could be potentially be used as a novel therapy for diabetic kidney disease and liver steatosis. PBI-4050 has been shown to treat fibrosis in several different animal models and is being prepared to enter into clinical development in 2013.
Other data confirms the effect of ProMetic's drug candidates on interstitial fibroblasts which are the principal cause of organ fibrosis.
"TGF-beta-stimulated fibroblasts secrete connective tissue growth factor (CTGF) which functions as a downstream mediator of TGF-beta action on fibroblastic cell types are important in collagen production. ProMetic's drug candidates have demonstrated the inhibition of CTGF and collagen production in murine and human fibroblasts and consequently to reduce kidney fibrosis in 5/6-nephrectomized rats and unilateral ureteral obstruction models", said Dr Lyne Gagnon, ProMetic's director of research and development, biology.